Platinum Investment Management Ltd. cut its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 16.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 155,101 shares of the company’s stock after selling 31,298 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Centessa Pharmaceuticals were worth $3,879,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the business. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after buying an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after buying an additional 1,449,000 shares in the last quarter. Commodore Capital LP boosted its stake in shares of Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after buying an additional 930,711 shares in the last quarter. TCG Crossover Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 8.5% in the third quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after buying an additional 245,664 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Centessa Pharmaceuticals by 0.6% in the third quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock valued at $62,042,000 after buying an additional 14,875 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.
Centessa Pharmaceuticals Stock Down 0.1%
CNTA opened at $39.72 on Friday. The business’s fifty day moving average is $39.64 and its two-hundred day moving average is $30.87. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market cap of $5.93 billion, a price-to-earnings ratio of -22.19 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $11.77 and a one year high of $40.26.
Wall Street Analyst Weigh In
CNTA has been the topic of a number of analyst reports. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $41.33.
Read Our Latest Stock Report on Centessa Pharmaceuticals
Insider Buying and Selling
In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 115,887 shares of company stock worth $3,346,523 in the last quarter. 4.09% of the stock is currently owned by insiders.
Centessa Pharmaceuticals Profile
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Stories
- Five stocks we like better than Centessa Pharmaceuticals
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report).
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
